LH Labcorp
NYSE · SEC CIK 920148 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $13.70M 20 sales by 10 insiders
- Filings on record
- 414 since 2021-08-03, latest 2026-09-03 08:21
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Schechter Adam H | Pres, CEO, Dir | — | $8.44M |
| Parham Richelle P | Dir | — | $1.78M |
| Wilkinson Peter J | SVP, CAO | — | $1.06M |
| ANDERSON KERRII B | Dir | — | $954.1K |
| Caveney Brian J | EVP, CMO, CSO, Pres of ED | — | $429.5K |
| Meltzer Jonathan C | EVP, Ops | — | $298.8K |
| Summy Amy B. | EVP, CMO | — | $283.4K |
| Kyle Kathryn W | EVP, CLO | — | $227.4K |
| van der Vaart Sandra D | EVP, Corp. Affairs | — | $156.0K |
| Vaughn Bryan T | EVP, Pres, Diagnostics | — | $67.0K |
Transactions 566
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-07 | 2023-02-04 | LH | Caveney Brian J | EVP, Pres of Diagnostics | M - OptEx | — | +560 | 16.3K | +4% | — |
| D | 2023-02-07 | 2023-02-06 | LH | Caveney Brian J | EVP, Pres of Diagnostics | F - Tax | $244.50 | -164 | 16.1K | -1% | -$40.1K |
| D | 2023-02-07 | 2023-02-06 | LH | Schechter Adam H | Pres, CEO, Dir | F - Tax | $244.50 | -1,368 | 21.7K | -6% | -$334.5K |
| D | 2023-02-07 | 2023-02-04 | LH | Schechter Adam H | Pres, CEO, Dir | M - OptEx | — | +3,507 | 23.1K | +18% | — |
| D | 2023-02-07 | 2023-02-06 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | F - Tax | $244.50 | -164 | 13.7K | -1% | -$40.1K |
| D | 2023-02-07 | 2023-02-04 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | M - OptEx | — | +560 | 13.9K | +4% | — |
| D | 2023-02-07 | 2023-02-06 | LH | Summy Amy B. | EVP, CMO | F - Tax | $244.50 | -83 | 577 | -13% | -$20.3K |
| D | 2023-02-07 | 2023-02-04 | LH | Summy Amy B. | EVP, CMO | M - OptEx | — | +267 | 660 | +68% | — |
| D | 2023-02-07 | 2023-02-06 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | F - Tax | $244.50 | -151 | 7,096 | -2% | -$36.9K |
| D | 2023-02-07 | 2023-02-04 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | M - OptEx | — | +560 | 7,247 | +8% | — |
| D | 2023-02-07 | 2023-02-04 | LH | EISENBERG GLENN A | CFO, EVP | M - OptEx | — | +970 | 35.4K | +3% | — |
| D | 2023-02-07 | 2023-02-06 | LH | EISENBERG GLENN A | CFO, EVP | F - Tax | $244.50 | -261 | 35.1K | -0.7% | -$63.8K |
| D | 2023-02-07 | 2023-02-06 | LH | BERBERIAN LANCE | EVP, CIO, CTO | F - Tax | $244.50 | -108 | 20.0K | -0.5% | -$26.4K |
| D | 2023-02-07 | 2023-02-04 | LH | BERBERIAN LANCE | EVP, CIO, CTO | M - OptEx | — | +374 | 20.1K | +2% | — |
| D | 2023-02-07 | 2023-02-04 | LH | Seltz Judith C | EVP, CHRO | M - OptEx | — | +280 | 1,882 | +17% | — |
| D | 2023-02-07 | 2023-02-06 | LH | Seltz Judith C | EVP, CHRO | F - Tax | $244.50 | -84 | 1,798 | -4% | -$20.5K |
| D | 2023-02-07 | 2023-02-06 | LH | van der Vaart Sandra D | EVP, CLO | F - Tax | $244.50 | -81 | 5,560 | -1% | -$19.8K |
| D | 2023-02-07 | 2023-02-04 | LH | van der Vaart Sandra D | EVP, CLO | M - OptEx | — | +300 | 5,641 | +6% | — |
| D | 2023-02-07 | 2023-02-04 | LH | Wilkinson Peter J | SVP, CAO | M - OptEx | — | +150 | 2,140 | +8% | — |
| D | 2023-02-07 | 2023-02-06 | LH | Wilkinson Peter J | SVP, CAO | F - Tax | $244.50 | -52 | 2,088 | -2% | -$12.7K |
| D | 2023-02-06 | 2023-02-02 | LH | Schechter Adam H | Pres, CEO, Dir | F - Tax | $254.99 | -805 | 19.6K | -4% | -$205.3K |
| D | 2023-02-06 | 2023-02-02 | LH | Schechter Adam H | Pres, CEO, Dir | M - OptEx | — | +2,773 | 20.4K | +16% | — |
| D | 2023-02-06 | 2023-02-02 | LH | BERBERIAN LANCE | EVP, CIO, CTO | F - Tax | $254.99 | -102 | 19.7K | -0.5% | -$26.0K |
| D | 2023-02-06 | 2023-02-02 | LH | BERBERIAN LANCE | EVP, CIO, CTO | M - OptEx | — | +297 | 19.8K | +2% | — |
| D | 2023-02-06 | 2023-02-02 | LH | Wilkinson Peter J | SVP, CAO | F - Tax | $254.99 | -41 | 1,990 | -2% | -$10.5K |
| D | 2023-02-06 | 2023-02-02 | LH | Wilkinson Peter J | SVP, CAO | M - OptEx | — | +117 | 2,031 | +6% | — |
| D | 2023-02-06 | 2023-02-02 | LH | Caveney Brian J | EVP, Pres of Diagnostics | F - Tax | $254.99 | -144 | 15.7K | -0.9% | -$36.7K |
| D | 2023-02-06 | 2023-02-02 | LH | Caveney Brian J | EVP, Pres of Diagnostics | M - OptEx | — | +443 | 15.9K | +3% | — |
| D | 2023-02-06 | 2023-02-02 | LH | Summy Amy B. | EVP, CMO | F - Tax | $254.99 | -77 | 393 | -16% | -$19.6K |
| D | 2023-02-06 | 2023-02-02 | LH | Summy Amy B. | EVP, CMO | M - OptEx | — | +220 | 470 | +88% | — |
| D | 2023-02-06 | 2023-02-02 | LH | Seltz Judith C | EVP, CHRO | M - OptEx | — | +220 | 1,679 | +15% | — |
| D | 2023-02-06 | 2023-02-02 | LH | Seltz Judith C | EVP, CHRO | F - Tax | $254.99 | -77 | 1,602 | -5% | -$19.6K |
| D | 2023-02-06 | 2023-02-02 | LH | EISENBERG GLENN A | CFO, EVP | F - Tax | $254.99 | -206 | 34.4K | -0.6% | -$52.5K |
| D | 2023-02-06 | 2023-02-02 | LH | EISENBERG GLENN A | CFO, EVP | M - OptEx | — | +767 | 34.6K | +2% | — |
| D | 2023-02-06 | 2023-02-03 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | S - Sale+OE | $253.90 | -324 | 6,687 | -5% | -$82.3K |
| D | 2023-02-06 | 2023-02-02 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | F - Tax | $254.99 | -119 | 7,011 | -2% | -$30.3K |
| D | 2023-02-06 | 2023-02-02 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | M - OptEx | — | +443 | 7,130 | +7% | — |
| D | 2023-02-06 | 2023-02-02 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | F - Tax | $254.99 | -141 | 13.3K | -1% | -$36.0K |
| D | 2023-02-06 | 2023-02-02 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | M - OptEx | — | +443 | 13.5K | +3% | — |
| D | 2023-02-06 | 2023-02-02 | LH | van der Vaart Sandra D | EVP, CLO | M - OptEx | — | +237 | 5,578 | +4% | — |
| D | 2023-02-06 | 2023-02-03 | LH | van der Vaart Sandra D | EVP, CLO | S - Sale+OE | $253.90 | -173 | 5,341 | -3% | -$43.9K |
| D | 2023-02-06 | 2023-02-02 | LH | van der Vaart Sandra D | EVP, CLO | F - Tax | $254.99 | -64 | 5,514 | -1% | -$16.3K |
| 2022-11-10 | 2022-11-08 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | S - Sale | $232.67 | -1,116 | 6,687 | -14% | -$259.7K | |
| D | 2022-11-08 | 2022-11-05 | LH | Caveney Brian J | EVP, Pres of Diagnostics | M - OptEx | — | +2,010 | 16.3K | +14% | — |
| D | 2022-11-08 | 2022-11-07 | LH | Caveney Brian J | EVP, Pres of Diagnostics | F - Tax | $233.77 | -894 | 15.4K | -5% | -$209.0K |
| D | 2022-11-08 | 2022-11-05 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | M - OptEx | — | +2,010 | 8,697 | +30% | — |
| D | 2022-11-08 | 2022-11-07 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | F - Tax | $233.77 | -894 | 7,803 | -10% | -$209.0K |
| D | 2022-11-03 | 2022-11-01 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | F - Tax | $222.56 | -892 | 13.0K | -6% | -$198.5K |
| D | 2022-11-03 | 2022-11-01 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | M - OptEx | — | +2,007 | 13.9K | +17% | — |
| D | 2022-11-03 | 2022-11-01 | LH | Schechter Adam H | Pres, CEO, Dir | M - OptEx | — | +2,007 | 18.5K | +12% | — |
| D | 2022-11-03 | 2022-11-01 | LH | Schechter Adam H | Pres, CEO, Dir | F - Tax | $222.56 | -893 | 17.6K | -5% | -$198.7K |
| D | 2022-11-03 | 2022-11-01 | LH | EISENBERG GLENN A | CFO, EVP | F - Tax | $222.56 | -5,348 | 33.8K | -14% | -$1.19M |
| D | 2022-11-03 | 2022-11-01 | LH | EISENBERG GLENN A | CFO, EVP | M - OptEx | — | +12.0K | 39.2K | +44% | — |
| M | 2022-09-28 | 2022-09-26 | LH | EISENBERG GLENN A | CFO, EVP | S - Sale | $210.62 | -25.0K | 30.0K | -45% | -$5.27M |
| 2022-09-13 | 2022-09-07 | LH | Caveney Brian J | EVP, Pres of Diagnostics | P - Purchase | $231.20 | +44.34 | 14.3K | +0.3% | +$10.3K | |
| DM | 2022-08-05 | 2022-08-03 | LH | EISENBERG GLENN A | CFO, EVP | S - Sale+OE | $253.94 | -32.1K | 53.7K | -37% | -$8.15M |
| DM | 2022-08-05 | 2022-08-03 | LH | EISENBERG GLENN A | CFO, EVP | M - OptEx | $147.12 | +32.1K | 63.6K | +102% | +$4.72M |
| DM | 2022-08-03 | 2022-08-01 | LH | Wilkinson Peter J | SVP, CAO | S - Sale+OE | $258.40 | -2,576 | 1,897 | -58% | -$665.6K |
| DM | 2022-08-03 | 2022-08-01 | LH | Wilkinson Peter J | SVP, CAO | M - OptEx | $146.59 | +817 | 2,654 | +44% | +$119.8K |
| D | 2022-08-03 | 2022-08-01 | LH | Wilkinson Peter J | SVP, CAO | F - Tax | $257.94 | -23 | 1,914 | -1% | -$5,933 |
| 2022-06-14 | 2022-06-07 | LH | Caveney Brian J | EVP, Pres of Diagnostics | P - Purchase | $242.19 | +42.01 | 14.2K | +0.3% | +$10.2K | |
| 2022-03-31 | 2022-03-29 | LH | van der Vaart Sandra D | EVP, CLO | S - Sale | $277.11 | -2,449 | 5,287 | -32% | -$678.6K | |
| 2022-03-31 | 2022-03-29 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | S - Sale | $277.11 | -2,356 | 6,606 | -26% | -$652.9K | |
| 2022-03-29 | 2022-03-28 | LH | BERBERIAN LANCE | EVP, CIO, CTO | F - Tax | $276.42 | -2,360 | 19.5K | -11% | -$652.4K | |
| 2022-03-29 | 2022-03-27 | LH | BERBERIAN LANCE | EVP, CIO, CTO | A - Grant | $0.00 | +5,310 | 21.9K | +32% | $0 | |
| 2022-03-29 | 2022-03-27 | LH | EISENBERG GLENN A | CFO, EVP | A - Grant | $0.00 | +14.1K | 58.4K | +32% | $0 | |
| 2022-03-29 | 2022-03-28 | LH | EISENBERG GLENN A | CFO, EVP | F - Tax | $276.42 | -6,286 | 52.2K | -11% | -$1.74M | |
| 2022-03-29 | 2022-03-25 | LH | Williams R Sanders | Dir | S - Sale | $272.98 | -572 | 6,431 | -8% | -$156.1K | |
| 2022-03-29 | 2022-03-28 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | F - Tax | $276.42 | -1,648 | 11.9K | -12% | -$455.5K | |
| 2022-03-29 | 2022-03-27 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | A - Grant | $0.00 | +3,707 | 13.6K | +38% | $0 | |
| D | 2022-03-29 | 2022-03-25 | LH | Wengel Kathryn E | Dir | M - OptEx | — | +603 | 603 | New | — |
| 2022-03-29 | 2022-03-28 | LH | Caveney Brian J | EVP, Pres of Diagnostics | F - Tax | $276.42 | -1,883 | 14.1K | -12% | -$520.5K | |
| 2022-03-29 | 2022-03-27 | LH | Caveney Brian J | EVP, Pres of Diagnostics | A - Grant | $0.00 | +4,241 | 16.0K | +36% | $0 | |
| 2022-03-29 | 2022-03-28 | LH | Wilkinson Peter J | SVP, CAO | F - Tax | $276.42 | -915 | 3,696 | -20% | -$252.9K | |
| 2022-03-29 | 2022-03-27 | LH | Wilkinson Peter J | SVP, CAO | A - Grant | $0.00 | +2,822 | 4,611 | +158% | $0 | |
| 2022-03-29 | 2022-03-28 | LH | van der Vaart Sandra D | EVP, CLO | F - Tax | $276.42 | -1,792 | 7,736 | -19% | -$495.3K | |
| 2022-03-29 | 2022-03-27 | LH | van der Vaart Sandra D | EVP, CLO | A - Grant | $0.00 | +4,241 | 9,528 | +80% | $0 | |
| 2022-03-29 | 2022-03-28 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | F - Tax | $276.42 | -1,885 | 8,962 | -17% | -$521.1K | |
| 2022-03-29 | 2022-03-27 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | A - Grant | $0.00 | +4,241 | 10.8K | +64% | $0 | |
| 2022-03-14 | 2022-03-10 | LH | Summy Amy B. | EVP, CMO | S - Sale | $262.21 | -249 | 250 | -50% | -$65.3K | |
| M | 2022-02-18 | 2022-02-16 | LH | NEUPERT PETER M | Dir | P - Purchase | $263.66 | +3,500 | 10.3K | +52% | +$922.8K |
| 2022-02-17 | 2022-02-15 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | S - Sale | $273.98 | -207 | 6,606 | -3% | -$56.7K | |
| 2022-02-17 | 2022-02-15 | LH | van der Vaart Sandra D | EVP, CLO | S - Sale | $273.98 | -207 | 5,287 | -4% | -$56.7K | |
| D | 2022-02-15 | 2022-02-12 | LH | EISENBERG GLENN A | CFO, EVP | M - OptEx | — | +940 | 44.6K | +2% | — |
| D | 2022-02-15 | 2022-02-14 | LH | EISENBERG GLENN A | CFO, EVP | F - Tax | $272.68 | -277 | 44.3K | -0.6% | -$75.5K |
| D | 2022-02-15 | 2022-02-14 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | F - Tax | $272.68 | -108 | 9,856 | -1% | -$29.4K |
| D | 2022-02-15 | 2022-02-12 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | M - OptEx | — | +317 | 9,964 | +3% | — |
| DM | 2022-02-15 | 2022-02-14 | LH | BERBERIAN LANCE | EVP, CIO, CTO | F - Tax | $272.68 | -799 | 16.7K | -5% | -$217.9K |
| DM | 2022-02-15 | 2022-02-12 | LH | BERBERIAN LANCE | EVP, CIO, CTO | M - OptEx | — | +2,708 | 17.4K | +18% | — |
| DM | 2022-02-15 | 2022-02-14 | LH | Caveney Brian J | EVP, Pres of Diagnostics | F - Tax | $272.68 | -778 | 11.8K | -6% | -$212.1K |
| DM | 2022-02-15 | 2022-02-12 | LH | Caveney Brian J | EVP, Pres of Diagnostics | M - OptEx | — | +2,638 | 10.2K | +35% | — |
| DM | 2022-02-15 | 2022-02-12 | LH | Wilkinson Peter J | SVP, CAO | M - OptEx | — | +867 | 2,050 | +73% | — |
| DM | 2022-02-15 | 2022-02-14 | LH | Wilkinson Peter J | SVP, CAO | F - Tax | $272.68 | -261 | 1,989 | -12% | -$71.2K |
| D | 2022-02-15 | 2022-02-12 | LH | van der Vaart Sandra D | EVP, CLO | M - OptEx | — | +284 | 5,571 | +5% | — |
| D | 2022-02-15 | 2022-02-14 | LH | van der Vaart Sandra D | EVP, CLO | F - Tax | $272.68 | -77 | 5,494 | -1% | -$21.0K |
| D | 2022-02-15 | 2022-02-12 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | M - OptEx | — | +284 | 6,890 | +4% | — |
| D | 2022-02-15 | 2022-02-14 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | F - Tax | $272.68 | -77 | 6,812 | -1% | -$21.0K |
| D | 2022-02-08 | 2022-02-04 | LH | EISENBERG GLENN A | CFO, EVP | F - Tax | $277.48 | -286 | 43.6K | -0.7% | -$79.4K |
| D | 2022-02-08 | 2022-02-04 | LH | EISENBERG GLENN A | CFO, EVP | M - OptEx | — | +970 | 43.9K | +2% | — |
| D | 2022-02-08 | 2022-02-04 | LH | van der Vaart Sandra D | EVP, CLO | F - Tax | $277.48 | -82 | 5,505 | -1% | -$22.8K |
Purchase Sale Sale after option exercise All abbreviations